Dalpiciclib: all 67 studies that test it

Page 1 of 1. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

• Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingNCT07892274Phase 3
• Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNCT07706933Not applicable
• Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
• IN10018 in Combination With Dalpiciclib for Progressive MeningiomasRecruitingNCT07652762Phase 1
• Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingNCT07618923Phase 2
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2
• Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingNCT07581834Phase 2
• Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain MetastasesNot yet recruitingNCT07539753Phase 2
• Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentRecruitingNCT07467330Phase 3
• Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingNCT07179939Phase 2
• Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNot yet recruitingNCT07101159Phase 2
• The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicable
• Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABCNot yet recruitingNCT06711094Not applicable
• Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Phase 2
• Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast CancerEnrolling by invitationNCT06650748Phase 2
• Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast CancerRecruitingNCT06637150Phase 3
• An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast CancerNot yet recruitingNCT06613373Phase 4
• Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 InhibitorNot yet recruitingNCT06556862Phase 2
• Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian CancerNot yet recruitingNCT06552858Phase 2
• Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II TrialRecruitingNCT06363734Phase 2
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast CancerRecruitingNCT06341894Phase 2
• Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid TumorsRecruitingNCT06243185Phase 2
• Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell CarcinomasRecruitingNCT06225921Phase 1
• Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06199271Phase 2
• Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast CancerRecruitingNCT06149130Phase 2
• Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）RecruitingNCT06107673Phase 2
• Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT05952128Phase 2
• Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI TherapyNot yet recruitingNCT05806671Phase 2
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2
• SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
• Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingNCT05228951Phase 2
• Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02RecruitingNCT05205200Phase 2
• SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic CancerNot yet recruitingNCT05185869Phase 2
• Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell CarcinomasStatus unknownNCT06109207Phase 1
• Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCCCompletedNCT05721443Phase 2
• Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb StudyCompletedNCT05586841Phase 1
• Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2
• Study of SHR6390 in Renal Insufficiency and Healthy SubjectsStatus unknownNCT05515289Phase 1
• Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerStatus unknownNCT05512780Phase 2
• Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast CancerStatus unknownNCT05512416Phase 2
• mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal CancerStatus unknownNCT05480280Phase 2
• Dalpiciclib Plus Letrozole and CapecitabineStatus unknownNCT05469750Phase 2
• A Phase I Clinical Study on SHR6390 in Healthy Chinese VolunteersCompletedNCT05354336Phase 1
• Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast CancerTerminatedNCT05176080Phase 1/2
• Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant TreatmentActive, not recruitingNCT05132790Not applicable
• An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 AntibodyStatus unknownNCT04866381Phase 2
• Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 NegativeActive, not recruitingNCT04842617Phase 3
• A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.Status unknownNCT04733417Phase 2
• Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy SubjectsCompletedNCT04667156Phase 1
• An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy ParticipantsStatus unknownNCT04631575Phase 1
• Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male VolunteersCompletedNCT04616742Phase 1
• Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II TrialActive, not recruitingNCT04486911Phase 2
• Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy SubjectsCompletedNCT04423601Phase 1
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• A Trial of SHR6390 in Healthy Caucasian VolunteersCompletedNCT04301804Phase 1
• Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast CancerStatus unknownNCT04293276Phase 2
• A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.Status unknownNCT04236310Phase 2
• A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03966898Phase 3
• A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerStatus unknownNCT03927456Phase 3
• Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerActive, not recruitingNCT03772353Phase 1/2
• A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCCStatus unknownNCT03601598Phase 1/2
• A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerCompletedNCT03481998Phase 1/2
• Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric CancerStatus unknownNCT03480256Phase 1
• A Study of SHR6390 in Advanced Solid Tumor PatientsCompletedNCT02684266Phase 1
• A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma PatientsStatus unknownNCT02671513Phase 1

← Dalpiciclib overview